在1985–1993年间，在湖南衡阳医学院病理生理学教研室任助教、讲师。期间1985-1988年以委托培养，师承王振义教授，在上海第二医学院攻读病理生理学硕士研究生。1993-1996年继续师承王振义教授在上海第二医科大学附属瑞金医院攻读血液学博士研究生，并留在上海血液学研究所工作。期间，1997年和1999年分别被破格晋升副研究员、研究员，1997年获得国家杰出青年科学基金的资助，并先后在法国巴黎Saint-Louis医院和美国Mount-Saint医学院工作1年和2年。2001年8月以中国科学院百人计划入选者回国，参加到上海生命科学研究院/上海交通大学医学院健康科学研究所，并于2002年初-2008年底担任上海交通大学医学院病理生理学教研室主任，2005年开始建设“细胞分化与凋亡”教育部重点实验室。期间，受聘为教育部长江特聘教授和国家重点基础研究973计划（2002-2008年）和重大研究计划（2009年-）项目首席科学家，并先后担任国务院学科评议组成员、中国病理生理学会常务理事、上海生物化学和分子生物学学会副理事长、上海生理学会副理事长，《生理学报》、《癌症》、《国际病理与临床科学杂志》副主编、《Open Hematology J》、《Acta Pharmacology Sina》、《中华医学杂志》、《科学通报》、《中国科学-生命科学辑》、《中国肿瘤生物治疗杂志》、《中华肿瘤防治杂志》等编委，Blood、Leukemia、JBC、Oncogene、JPR，Cell Death and Differentiation、等近30本国际期刊的审稿人。
      1993-1997年间，在王振义和陈竺教授等指导下，作为主要实施者，开展三氧化二砷(ATO)和ATRA治疗急性早幼粒白血病（APL）的机制和药代动力学研究，在《Blood》和《LEUKEMIA》发表系列论文，《Science》发表了专题新闻，并连续9年在我国单篇论文被引证数排名中据前8名。两位导师在创新能力、科研思维、学术道德等方面的指导使他终身受益。1997年，获得国家杰青基金后，作为通讯作者，他和他的同事、研究生在《JNCI》报告ATO对恶性淋巴细胞的凋亡诱导及其机制。该杂志发表了“editorial”。在探讨ATO诱导细胞凋亡和部分分化的双重效应的分子机制的基础上，提出ATO治疗APL的相对完整的机制模型，并报道ATO诱导细胞分裂阻滞和凋亡的关系，为促进ATO作为治疗APL药物被美国FDA批准和临床推广做出了贡献。
      随后，在国家科技部973计划、国家自然科学基金重点项目和重大项目以及上海市的资助下，他和他的同事继续致力于各种类型急性髓细胞性白血病（AML）病理生理学和化学生物学研究，提出以“低氧-HIF-1a-C/EBPa/Runx1”为主轴的AML细胞分化理论体系，为白血病治疗学和发病学研究方面形成了新的学术生长点，引起国际同行的重视和追踪。同时，开展基于活性小分子化合物的化学蛋白质组学研究，发现去磷脂层酶1（PLSCR1）的抗AML效应，并发现新的诱导AML细胞凋亡的活性化合物，为抗白血病药物研发提供了基础。迄至2009年6月，共发表SCI论文（不含综述）67篇。其中，作为通讯作者发表30篇（包括影响因子>10的刊物4篇，在影响因子5-10的刊物18篇，包括血液学领域排位第二的《Leukemia》7篇），作为第一作者发表5篇，这些论著被他人总引用3031次。同时，他先后获得中华医学科技一等奖、上海市科技进步一等奖、上海自然科学一等奖和国家自然科学二等奖等，并分别获得中国青年科技奖、教育部长江特聘教授、上海十大杰出青年、上海自然科学牡丹奖、上海科技英才、上海市劳动模范和全国先进工作者等荣誉称号。

1. Chen GQ, Shen ZX, Wu F, Han JY, Miao JM, Zhong HJ,Li XS, Zhao JQ, Zhu J, Fang ZW, Chen SJ, Chen Z,Wang ZY.Pharmacokinetics and efficacy of low-dose all-transretinoic acid in the treatment of acute promyelocytic leukemia. Leukemia. 1996; 10(5):825-828.
2. Guo-Qiang Chen, Jun Zhu, Xue-Geng Shi,et al. In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (As203) in the Treatment of Acute Promyelocytic Leukemia: As203 Induces NB4 Cell Apoptosis With Downregulation of Bcl-2 Expression and Modulation of PML-RARdPML Proteins. Blood. 1996; 88, 3, 1052-1061.
3. SY Zhang, J Zhu, GQ Chen, XX Du, LJ Lu, Z Zhang, HJ Zhong, HR Chen, ZY Wang, R Berger,M Lanotte, S Waxman, Z Chen and SJ Chen. Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice. Blood. 1996; 87, 8, 3404-3409.
4. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As2O3 Exerts Dose-Dependent Dual Effects on APL Cells. Blood. 1997;89(9):3345-3353.
5. Zhi-Xiang Shen, Guo-Qiang Chen, Jian-Hua Ni, et al. Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood. 1997; 89, 9, 3354-3360.
6. Xin-Hua Zhu, Yu-Lei Shen, Yong-kuiJing,et al. Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations. Journal of the National Cancer Institute. 1999; 91, 9, 772-778.
7. J Zhu, W-M Guo, Y-Y Yao, W-L Zhao, L Pan, X Cai, B Ju, G-L Sun, H-L Wang, S-J Chen, G-Q Chen, J Caen,Z Chen and Z-Y Wang. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia. 1999; 13, 1062–1070.
8. Chao Niu, Hua Yan, Ting Yu,et al. Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients. Blood. 1999; 94, 10, 3315-3324.
9. X Cai, Y-L Shen, Q Zhu, P-M Jia, Y Yu, L Zhou, Y Huang, J-W Zhang, S-M Xiong, S-J Chen, Z-Y Wang, Z Chen and G-Q Chen. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000; 14, 262–270.
10. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitroand in vivo studies. Semin Hematol. 2001; 38(1):26-36.
11. Zhao WL, Chen SJ, Shen Y, Xu L, Cai X, Chen GQ, Shen ZX, Chen Z, Wang ZY. Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies. Leukemia and Lymphoma. 2001; 42, 1265–1273.
12. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. BLOOD. 2001; 97, 1, 264-269.
13. Jia P, Chen GQ, Huang X, Cai X, Yang J, Wang L, Zhou Y, Shen Y, Zhou L, Yu Y, Chen S, Zhang X, Wang Z. Arsenic trioxide induces multiple myeloma cell apoptosis viadisruption of mitochondrial transmembrane potentials and activation of caspase-3. Chinese Medical. 2001; 114, 1 :19-24.
14. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol. 2002. 39(2 Suppl 1):22-26.
15. Gu BW, Xiong H, Zhou Y, Chen B, Wang L, Dong S, Yu ZY, Lu LF, Zhong M, Yin HF, Zhu GF, Huang W, Ren SX, Gallagher RE, Waxman S, Chen GQ, et al. Variant-type PML-RARα fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding sequence from intron 2 of the RARα gene and identification of a new clinical subtype resistant to retinoic acid therapy. PNAS. 2002; 99, 11, 7640-7645.
16. Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ, Chen Z. Treatment of Acute Promylocytic Leukemia with ATRA and As2O3. Cancer Biology & Therapy. 2002; 1:6, 614-620.
17. Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S. Methylated Metabolites of Arsenic Trioxide Are More Potent Than Arsenic Trioxide as Apoptotic but not Differentiation Inducers in Leukemia and Lymphoma Cells. CANCER RESEARCH. 2003; 63, 1853–1859.
18. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003; 17, 1333–1337.
19. Huang Y, Du KM, Xue ZH, Yan H, Li D, Liu W, Chen Z, Zhao Q, Tong JH, Zhu YS, Chen GQ. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1a. Leukemia. 2003; 17(11): 2065-2073.
20. Zhao Q, Tao J, Zhu Q, Jia PM, Dou AX, Li X, Cheng F, Waxman S, Chen GQ, Chen SJ, Lanotte M, Chen Z, Tong JH. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia. 2004; 18, 285–292.
21. Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG, Shen WZ, Zhao J, Zhou Q, Chen Z, Sims PJ, Wiedmer T, Chen GQ. Protein kinase Cd mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood. 2004; 104(12): 3731-3738.
21. Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, Zhang J, Chen GQ, Chen SJ, Chen Z. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004; 104(13): 4219-4225.
22. Yan H, Peng ZG, Wu YL, Jiang Y, Yu Y, Huang Y, Zhu YS, Zhao Q, Chen GQ. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica. 2005; 90 (12): 1607-1616.
23. Zhao KW, Li D, Zhao Q, Huang Y, Silverman RH, Sims PJ, Chen GQ. Interferon-a-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cd and JNK. J Biol Chem. 2005; 280 (52): 42707-42714.
24. Fu GH, Wang Y, Xi YH, Guo ZW, Liu XB, Bai SZ, Yang BF, Chen GQ. As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein. J Drug Target. 2005; 13 (4): 235-243.
25. Jiang Y, Xue ZH, Shen WZ, Du KM, Yan H, Yu Y, Peng ZG, Song MG, Tong JH, Chen Z, Huang Y, Lubbert M, Chen GQ. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1a that augments transcriptional activity of CCAAT/enhancer-binding protein-a. Leukemia. 2005; 19 (7): 1239-1247.
26. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, Zhang WH, Peng CH, Zhang SD, Li HW, Chen GQ. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology. 2005; 68 (1): 79-86.
27. Fu GH, Wang Y, Xi YH, Shen WW, Pan XY, Shen WZ, Jiang XS, Chen GQ. Direct interaction and cooperative role of tumor suppressor p16 with band 3 (AE1). Febs Lett. 2005; 579 (10): 2105-2110.
28. Song MG, Gao SM, Du KM, Xu M, Yu Y, Zhou YH, Wang Q, Chen Z, Zhu YS, Chen GQ. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cd-dependent mechanisms. Blood. 2005; 105(9): 3714-3721.
29. Xue ZH, Jiang Y, Yu Y, Wang LS, Chen GQ, Zhao Q. Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1a protein. Biochem Bioph Res Co. 2005; 332(4): 1140-1145.
30. Li Z, Liu Q, Song M, Zheng Y, Nan P, Cao Y, Chen GQ, Li Y, Zhong Y. Detecting correlation between sequence and expression divergences in a comparative analysis of human serpin genes. Biosystems. 2005; 82 (3): 226-234.
31. Fu GH, Wang Y, Xi YH, Guo ZW, Liu XB, Bai SZ, Yang BF, Chen GQ. AS2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein. Journal of Drug Targeting. 2005;13(4);235-243.
32. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ. AML1-ETO and C-KIT mutation/overexpression in t (8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. P Natl Acad Sci USA. 2005; 102(4): 1104-1109.
33. Zhang L, Wang LS, Xu Y, Xia L, Chen WL, Zheng Y, Chen GQ. Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein. Chinese J Physiol. 2006; 49 (4): 182-191.
34. Huang Y, Zhao Q, Zhou CX, Gu ZM, Li D, Xu HZ, Wiedmer T, Sims PJ, Zhao KW, Chen GQ. Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells. Oncogene. 2006; 25 (50): 6618-6627.
35. Han YH, Xia L, Song LP, Zheng Y, Chen WL, Zhang L, Huang Y, Chen GQ, Wang LS. Comparative proteomic analysis of hypoxia-treated and untreated human leukemic U937 cells. Proteomics. 2006; 6 (11): 3262-74.
36. Lu Y, Xu YB, Yuan TT, Song MG, Lubbert M, Fliegauf M, Chen GQ. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia. 2006; 20 (6): 987-993.
37. Guo M, Song LP, Jiang Y, Liu W, Yu Y, Chen GQ. Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1a independent mechanisms. Apoptosis. 2006; 11(1): 67-77.
38. Liu W, Guo M, Xu YB, Li D, Zhou ZN, Wu YL, Chen Z, Kogan SC, Chen GQ. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood. 2006; 107 (2): 698-707.
39. Jin X, Xia L, Wang LS, Shi JZ, Zheng Y, Chen WL, Zhang L, Liu ZG, Chen GQ, Fang NY. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics. 2006; 6 (6): 1948-1956.
40. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte M, Tong JH, Chen GQ, Segal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci. 2006; 119(Pt 13):2797-2806.
41. Li X, Xu YB, Wang Q, Lu Y, Zheng Y, Wang YC, Lubbert M, Zhao KW, Chen GQ. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells. J Cell Physiol. 2006; 208 (3): 594-601.
42. Xiao S, Li D, Zhu HQ, Song MG, Pan XR, Jia PM, Peng LL, Dou AX, Chen GQ, Chen SJ, Chen Z, Tong JH. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. P Natl Acad Sci USA. 2006; 103 (44):16448-16453.
43. Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, Jia M, Zhao Q, Cai H, Han ZC, Yang R, Chen GQ, Zhao RC. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Bioph Res Co. 2006; 347 (1): 12-21.
44. Pan XY, Chen GQ, Cai L, Buscemi S, Fu GH. Anion exchanger 2 mediates the action of arsenic trioxide. Brit J Haematol. 2006; 134 (5): 491-499.
45. Yu Y, Wang LS, Shen SM, Xia L, Zhang L, Zhu YS, Chen GQ. Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells. J Proteome Res. 2007; 6(9): 3808-3818.
46. Xu M, Li D, Lu Y, Chen GQ. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene. Exp Hematol. 2007; 35(8): 1249-1255.
47. Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL, Chen GQ. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cd. Leukemia. 2007; 21 (7): 1488-1495.
48. Liu W, Zhu YS, Guo M, Yu Y, Chen GQ. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leukemia Res. 2007; 31(11): 1565-1574.
49. Shen WW, Wu J, Cai L, Liu BY, Gao Y, Chen GQ, Fu GH. Expression of Anion Exchanger 1 Sequestrates p16 in the Cytoplasm in Gastric and Colonic Adenocarcinoma. Neoplasia. 2007; 9(10) , 812 – 819.
50. Wang Y, Wu SF, Chen GQ, Fu GH. Effect of block deletions in the C-terminus on the functional expression of human anion exchanger 1 (AE1). Molecular Membrane Biology. 2007, 24(1): 65-73.
51. Gao FH, Wang Q, Wu YL, Li X, Zhao KW, Chen GQ. c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression. Biochem Bioph Res Co. 2007; 356 (2): 505-511.
52. Chen GQ, Wang LS, Wu YL, Yu Y. Leukemia, an effective model for chemical biology and target therapy. Acta Pharmacol Sin. 2007; 28 (9): 1316-1324.
53. Qiu J, Huang Y, Chen GQ, Chen Z, Tweardy DJ, Dong S. Aberrant chromatin remodeling by retinoic acid receptor a fusion proteins assessed at the single-cell level. Mol Biol Cell. 2007; 18(10): 3941-3951. 34. Wang Y, Wu SF, Chen GQ, Fu GH. Effect of block deletions in the C-terminus on the functional expression of human anion exchanger 1 (AE1). Mol Membr Biol. 2007; 24 (1):65-73.
54. Huang Y, Qiu JH, Chen GQ, Dong S. Coiled-coil domain of PML is essential for the aberrant dynamics of PML-RARa, resulting in sequestration and decreased mobility of SMRT. Biochem Bioph Res Co. 2008; 365(2): 258–265.
55. Yang L, Jiang Y, Wu SF, Zhou MY, Wu YL and Chen GQ. CCAAT/enhancer-binding protein a antagonizes transcriptional activity of hypoxia-inducible factor 1 a with direct protein–protein interaction. Carcinogenesis. 2008; 29(2): 291–298.
56. Song LP, Zhang J, Wu SF, Huang Y, Zhao Q, Cao JP, Wu YL, Wang LS, Chen GQ. Hypoxia-inducible factor-1a-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene. 2008; 27(4): 519–527.
57. Peng ZG, Zhou MY, Huang Y, Qiu JH, Wang LS, Liao SH, Dong S Chen GQ. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1a. Oncogene. 2008; 27(6): 839–847. 39. Lu Y, Peng ZG, Yuan TT, Yin QQ, Xia L, Chen GQ. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity. Leukemia. 2008; 22(2): 378–386.
58. Jin X, Wang LS, Xia L, Zheng Y , Meng C, Yu Y, Chen GQ, Fang NY.  Hyper-phosphorylation of a-enolase in hypertrophied left ventricle of spontaneously hypertensive rat. Biochem Bioph Res Co. 2008; 371(4): 804–809.
59. Zhang J, Song LP, Huang Y, Zhao Q, Zhao KW, Chen GQ. Accumulation of hypoxia-inducible factor-1a protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica. 2008; 93(10): 1480-1487.
60. Wang S, Zheng Y, Yu Y, Xia L, Chen GQ, Yang YZ, Wang LS. Phosphorylation of b-actin by protein kinase C-delta in camptothecin analog-induced leukemic cell apoptosis. Acta Pharmacol Sin. 2008; 29 (1): 135–142.
61. Zheng Y, Wang LS, Xia L, Han YH, Liao SH, Wang XL, Cheng JK, Chen GQ. NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: The potential role in proteolytic activation of PKCd and apoptosis. Proteomics. 2009; 9(8): 2064–2075.
62. Zhao M, Duan XF, Wen DH, Chen GQ. PU.1, a novel capase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells. Biochem Bioph Res Co. 2009; 382(2): 508–513.
63. Meng C, Jin X, Xia L, Shen SM, Wang XL, Cai J, Chen GQ, Wang LS, Fang NY. Alterations of mitochondrial enzymes contribute to cardiac hypertrophy before hypertension development in sponeously hypertensive rats. J Proteome Res. 2009; 8 (5): 2463-2475.
64. Yuan TT, Huang Y, Zhou CX, Yu Y, Wang LS, Zhuang HY, Chen GQ. Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis. Apoptosis. 2009; 14(5): 699–710.
65. Chen S, Han YH, Zheng Y, Zhao M, Yan H, Zhao Q, Chen GQ, Li D. NDRG1 contributes to retinoic acid-induced differentiation of leukemic cells. Leukemia Res. 2009; 33(8): 1108–1113.
66. Zhang N, Zhang HW, Xia L, Zheng Y, Yu Y, Zhu YS, Chen GQ, Di W. NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1a protein in human ovarian cancer cells. Cancer Lett. 2009; 278(2): 139–144.
67. Zhao Y, Pu JX, Huang SX, Wu YL, Yang YB, Xiao WL, Han QB, Chen GQ, Sun HD. ent-kaurane diterpenoids from Isodon scoparius. J Nat Prod. 2009; 72(1): 125–129.
68. Chen LY, Pan WW, Chen M, Li JD, Liu W, Chen GQ, Huang S, Papadimos TJ, Pan ZK. Synergistic induction of inflammation by bacterial products lipopolysaccharide and fMLP: an important microbial pathogenic mechanism. J Immunol. 2009; 182(4): 2518 –2524.
69. Yu H, Meng Y, Wang LS, Jin X, Gao LF, Zhou L, Ji K, Li Y, Zhao LJ, Chen GQ, Zhao XJ Yang B. Differential protein expression in heart in UT-B null mice with cardiac conduction defects. Proteomics. 2009; 9(3): 504–511. 52.
70. Tan C, Cai LQ, Wu W, Qiao Y, Julianne Imperato-McGinley, Chen GQ, Zhu YS. NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemoth Pharm. 2009; 63(2): 303-312.
71. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG, Fang JY. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol. 2009 Jun 11. [Epub ahead of print]54. Xiong H, Chen ZF, Liang QC, Du W, Chen HM, Su WY, Chen GQ, Han ZG, Fang JY. Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signaling. J Cell Mol Med. 2009 Jan 16. [Epub ahead of print]
72. Liao SH, Zhao XY, Han YH, Zhang J, Wang LS, Xia L, Zhao KW, Zheng Y, Guo M, Chen GQ. Proteomics-based identification of two novel direct targets of hypoxia- inducible factor-1a and their potential roles in migration/invasion of cancer cells. Proteomics. 2009 Jul 27. [Epub ahead of print].
73. Yue F, Wang LS, Xia L, Wang XL, Feng B, Lu AG, Chen GQ, Zheng MH. Modulated T-complex protein 1 zeta and peptidyl-prolyl cis-trans isomerase B are two novel indicators for evaluating lymph node metastasis in colorectal cancer: evidence from proteomics and bioinformatics. Proteomics Clinical Application. 2009, in press
74. Zhao M, Duan XF, Zhao XY, Zhang B, Lu Y, Liu W, Cheng JK, Chen GQ. Protein kinase Cd stimulates proteasome-dependent degradation of C/EBPα during apoptosis induction of leukemic cells. PlosONE .2009; 4(8): e6552.                                               
75. Zhang J, Chen GQ. Hypoxia-HIF-1α-C/EBPα/Runx1 signaling in leukemic cell differentiation. Pathophysiology. 2009; 16, 297-303.
76. Liao SH, Zhao XY, Han YH, Zhang J, Wang LS, Xia L, Zhao KW, Zheng Y, Guo M, Chen GQ. Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1 and their potential roles in migration/invasion of cancer cells. Proteomics. 2009 Jul 27;9(15):3901-3912.
77.Xiong H, Chen ZF, Liang QC, Du W, Chen HM, Su WY, Chen GQ, Han ZG, Fang JY. Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signaling. J Cell Mol Med. 2009 Jan 16. [Epub ahead of print] PMID: 19175468 [PubMed - as supplied by publisher]
78.He F, Xiao WL, Pu JX, Wu YL, Zhang HB, Li XN, Zhao Y, Yang LB, Chen GQ, Sun HD. Cytotoxic ent-kaurane diterpenoids from Isodon sinuolata. Phytochemistry. 2009; 70(11-12):1462-1466. Epub 2009 Aug 25.
79. Gao FH, Wu YL, Zhao M, Liu CX, Wang LS, Chen GQ. Protein Kinase C-δ mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp Cell Res. 2009;315(19):3250-3258.
80. Duan XF, Wu YL, Xu HZ, Zhao M, Zhuang HY, Wang XD, Yan H, Chen GQ. Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. Chem Biol Interact. 2010;183 : 222-230
81. Shen SM, Yu Y, Wu YL, Cheng JK, Wang LS, Chen GQ. Downregulation of ANP32B, a novel substrate of caspase-3, enhances caspase-3 activation and apoptosis induction in myeloid leukemic cells. Carcinogenesis. 2010;31(3):419-426.
82. Wu SF, Huang Y, Hou JK, Yuan TT, Zhou CX, Zhang J, Chen GQ.The downregulation of onzin expression by PKCepsilon-ERK2 signaling and its potential role in AML cell differentiation. Leukemia. 2010; 24(3):544-551.
83. Xu HZ, Huang Y, Wu YL, Zhao Y, Xiao WL, Lin QS, Sun HD, Dai W, Chen GQ. Pharicin A, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic catastrophe of cancer cells by interfering with BubR1 function. Cell Cycle. 2010; 9(14): 1-11.